Published in
Elsevier, Journal of Biological Chemistry, 34(287), p. 28386-28397, 2012
Links
- ORCID
- ORCID
- Elsevier
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.jbc.org] | PDF
Tools
α-Galactosidase Aggregation Is a Determinant of Pharmacological Chaperone Efficacy on Fabry Disease Mutants
Journal article published in 2012 by
Aleksandra Siekierska,
Greet De Baets,
Joke Reumers,
Rodrigo Gallardo,
Stanislav Rudyak,
Kerensa Broersen 
,
Jose Couceiro,
Joost Van Durme,
Joost Schymkowitz,
Frederic Rousseau
,
Jose Couceiro,
Joost Van Durme,
Joost Schymkowitz,
Frederic Rousseau
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Background: Deficiency in α-galactosidase activity leads to Fabry disease, for which treatment employing pharmacological chaperones is being developed.